Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Longitudinal analysis of health-related quality of life (HRQoL) remains unstandardized and compromises comparison of results between trials. In oncology, despite available statistical approaches, results are poorly used to change standards of care, mainly due to lack of standardization and the ability to propose clinical meaningful results. In this context, the time to deterioration (TTD) has been proposed as a modality of longitudinal HRQoL analysis for cancer patients. As for tumor response and progression, we propose to develop RECIST criteria for HRQoL.
Several definitions of TTD are investigated in this paper. We applied this approach in early breast cancer and metastatic pancreatic cancer with a 5-point minimal clinically important difference. In breast cancer, TTD was defined as compared to the baseline score or to the best previous score. In pancreatic cancer (arm 1: gemcitabine with FOLFIRI.3, arm 2: gemcitabine alone), the time until definitive deterioration (TUDD) was investigated with or without death as event.
In the breast cancer study, 381 women were included. The median TTD was influenced by the choice of the reference score. In pancreatic cancer study, 98 patients were enrolled. Patients in Arm 1 presented longer TUDD than those in Arm 2 for most of HRQoL scores. Results of TUDD were slightly different according to the definition of deterioration applied.
Currently, the international ARCAD group supports the idea of developing RECIST for HRQoL in pancreatic and colorectal cancer with liver metastasis, with a view to using HRQoL as a co-primary endpoint along with a tumor parameter.
- Beitz, J., Gnecco, C., & Justice, R. (1996). Quality-of-life end points in cancer clinical trials: The US food and drug administration perspective. Journal of the National Cancer Institute Monographs, (20), 7–9.
- Johnson, JR, Temple, R (1985) Food and drug administration requirements for approval of new anticancer drugs. Cancer Treatment Reports 69: pp. 1155-1159
- Lipscomb, J., Donaldson, M. S., Arora, N. K., Brown, M. L., Clauser, S. B., Potosky, A. L., et al. (2004). Cancer outcomes research. Journal of the National Cancer Institute Monographs, (33), 178–197.
- Fairclough, DL, Peterson, HF, Chang, V (1998) Why are missing quality of life data a problem in clinical trials of cancer therapy?. Statistics in Medicine 17: pp. 667-677 CrossRef
- Ross, L, Thomsen, BL, Boesen, EH, Johansen, C (2004) In a randomized controlled trial, missing data led to biased results regarding anxiety. Journal of Clinical Epidemiology 57: pp. 1131-1137 CrossRef
- Curran, D, Bacchi, M, Schmitz, SF, Molenberghs, G, Sylvester, RJ (1998) Identifying the types of missingness in quality of life data from clinical trials. Statistics in Medicine 17: pp. 739-756 CrossRef
- Steen, K, Curran, D, Molenberghs, G (2001) Sensitivity analysis of longitudinal binary quality of life data with drop-out: an example using the EORTC QLQ-C30. Statistics in Medicine 20: pp. 3901-3920 CrossRef
- Cole, BF, Bonetti, M, Zaslavsky, AM, Gelber, RD (2005) A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. Statistics in Medicine 24: pp. 2317-2334 CrossRef
- Fairclough, DL, Peterson, HF, Cella, D, Bonomi, P (1998) Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statistics in Medicine 17: pp. 781-796 CrossRef
- Pauler, DK, McCoy, S, Moinpour, C (2003) Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Statistics in Medicine 22: pp. 795-809 CrossRef
- Troxel, AB, Fairclough, DL, Curran, D, Hahn, EA (1998) Statistical analysis of quality of life with missing data in cancer clinical trials. Statistics in Medicine 17: pp. 653-666 CrossRef
- Liao, K, Freres, DR, Troxel, AB (2012) A transition model for quality-of-life data with non-ignorable non-monotone missing data. Statistics in Medicine 31: pp. 3444-3466 CrossRef
- Ubel, PA, Peeters, Y, Smith, D (2010) Abandoning the language of “response shift”: A plea for conceptual clarity in distinguishing scale recalibration from true changes in quality of life. Quality of Life Research 19: pp. 465-471 CrossRef
- Wiklund, I (2004) Assessment of patient-reported outcomes in clinical trials: The example of health-related quality of life. Fundamental & Clinical Pharmacology 18: pp. 351-363 CrossRef
- Bullinger, M (2002) Assessing health related quality of life in medicine. An overview over concepts, methods and applications in international research. Restorative Neurology and Neuroscience 20: pp. 93-101
- Gibbons, FX (1999) Social comparison as a mediator of response shift. Social Science and Medicine 48: pp. 1517-1530 CrossRef
- Sprangers, MA, Schwartz, CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Social Science and Medicine 48: pp. 1507-1515 CrossRef
- Pan, AW, Chen, YL, Chung, LI, Wang, JD, Chen, TJ, Hsiung, PC (2012) A longitudinal study of the predictors of quality of life in patients with major depressive disorder utilizing a linear mixed effect model. Psychiatry Research 198: pp. 412-419 CrossRef
- Hunger, M, Doring, A, Holle, R (2012) Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Medical Research Methodology 12: pp. 144 CrossRef
- Penar-Zadarko, B, Binkowska-Bury, M, Wolan, M, Gawelko, J, Urbanski, K (2013) Longitudinal assessment of quality of life in ovarian cancer patients. European Journal of Oncology Nursing 17: pp. 381-385 CrossRef
- Mantegna, G, Petrillo, M, Fuoco, G, Venditti, L, Terzano, S, Anchora, LP, Scambia, G, Ferrandina, G (2013) Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. BMC Cancer 13: pp. 127 CrossRef
- Rathod, S, Gupta, T, Ghosh-Laskar, S, Murthy, V, Budrukkar, A, Agarwal, J (2013) Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): Evidence from a prospective randomized study. Oral Oncology 49: pp. 634-642 CrossRef
- Cnaan, A, Laird, NM, Slasor, P (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine 16: pp. 2349-2380 CrossRef
- Fairclough, DL (2010) Design and analysis of quality of life studies in clinical trials. CRC Press, Boca Raton
- Little, RJ, Wang, Y (1996) Pattern-mixture models for multivariate incomplete data with covariates. Biometrics 52: pp. 98-111 CrossRef
- Hogan, JW, Laird, NM (1997) Mixture models for the joint distribution of repeated measures and event times. Statistics in Medicine 16: pp. 239-257 CrossRef
- Thijs, H, Molenberghs, G, Michiels, B, Verbeke, G, Curran, D (2002) Strategies to fit pattern-mixture models. Biostatistics 3: pp. 245-265 CrossRef
- Glas, CA, Geerlings, H, Laar, MA, Taal, E (2009) Analysis of longitudinal randomized clinical trials using item response models. Contemporary Clinical Trials 30: pp. 158-170 CrossRef
- Ayala, R (2009) The theory and practice of item response theory. Guilford Press, New York
- Bonnetain, F, Dahan, L, Maillard, E, Ychou, M, Mitry, E, Hammel, P, Legoux, JL, Rougier, P, Bedenne, L, Seitz, JF (2010) Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer 46: pp. 2753-2762 CrossRef
- Hamidou, Z, Dabakuyo, TS, Mercier, M, Fraisse, J, Causeret, S, Tixier, H, Padeano, MM, Loustalot, C, Cuisenier, J, Sauzedde, JM, Smail, M, Combier, JP, Chevillote, P, Rosburger, C, Arveux, P, Bonnetain, F (2011) Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer. Oncologist 16: pp. 1458-1468 CrossRef
- Goel, MK, Khanna, P, Kishore, J (2010) Understanding survival analysis: Kaplan-Meier estimate. International Journal of Ayurveda Research 1: pp. 274 CrossRef
- Dabakuyo, TS, Guillemin, F, Conroy, T, Velten, M, Jolly, D, Mercier, M, Causeret, S, Cuisenier, J, Graesslin, O, Gauthier, M, Bonnetain, F (2013) Response shift effects on measuring post-operative quality of life among breast cancer patients: A multicenter cohort study. Quality of Life Research 22: pp. 1-11 CrossRef
- Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, Filiberti, A, Flechtner, H, Fleishman, SB, Haes, JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85: pp. 365-376 CrossRef
- Sprangers, MA, Groenvold, M, Arraras, JI, Franklin, J, Velde, A, Muller, M, Franzini, L, Williams, A, Haes, HC, Hopwood, P, Cull, A, Aaronson, NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. Journal of Clinical Oncology 14: pp. 2756-2768
- Andrykowski, MA, Donovan, KA, Jacobsen, PB (2009) Magnitude and correlates of response shift in fatigue ratings in women undergoing adjuvant therapy for breast cancer. Journal of Pain and Symptom Management 37: pp. 341-351 CrossRef
- Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A. ObotEQoLG. EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC 2001 ed2001.
- Team, R. D. C. R. A language and environment for statistical computing. Vienna, Austria: R foundation for statistical computing. ISBN 3-900051-07-0, http://www.R-project.org/.
- Gourgou-Bourgade, S, Bascoul-Mollevi, C, Desseigne, F, Ychou, M, Bouche, O, Guimbaud, R, Becouarn, Y, Adenis, A, Raoul, JL, Boige, V, Berille, J, Conroy, T (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of Clinical Oncology 31: pp. 23-29 CrossRef
- Wimberger, P, Gilet, H, Gonschior, AK, Heiss, MM, Moehler, M, Oskay-Oezcelik, G, Al-Batran, SE, Schmalfeldt, B, Schmittel, A, Schulze, E, Parsons, SL (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: Results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Annals of Oncology 23: pp. 1979-1985 CrossRef
- Korfage, IJ, Koning, HJ, Essink-Bot, ML (2007) Response shift due to diagnosis and primary treatment of localized prostate cancer: A then-test and a vignette study. Quality of Life Research 16: pp. 1627-1634 CrossRef
- Oort, FJ (2005) Using structural equation modeling to detect response shifts and true change. Quality of Life Research 14: pp. 587-598 CrossRef
- Schwartz, CE, Sprangers, MA (1999) Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science and Medicine 48: pp. 1531-1548 CrossRef
- Sprangers, MA, Dam, FS, Broersen, J, Lodder, L, Wever, L, Visser, MR, Oosterveld, P, Smets, EM (1999) Revealing response shift in longitudinal research on fatigue–the use of the thentest approach. Acta Oncologica 38: pp. 709-718 CrossRef
- McPhail, S, Haines, T (2010) Response shift, recall bias and their effect on measuring change in health-related quality of life amongst older hospital patients. Health and Quality of Life Outcomes 8: pp. 65 CrossRef
- Oort, FJ, Visser, MR, Sprangers, MA (2005) An application of structural equation modeling to detect response shifts and true change in quality of life data from cancer patients undergoing invasive surgery. Quality of Life Research 14: pp. 599-609 CrossRef
- Blanchin, M, Hardouin, JB, Neel, T, Kubis, G, Blanchard, C, Mirallie, E, Sebille, V (2011) Comparison of CTT and Rasch-based approaches for the analysis of longitudinal patient reported outcomes. Statistics in Medicine 30: pp. 825-838
- Sebille, V, Hardouin, JB, Neel, T, Kubis, G, Boyer, F, Guillemin, F, Falissard, B (2010) Methodological issues regarding power of classical test theory (CTT) and item response theory (IRT)-based approaches for the comparison of patient-reported outcomes in two groups of patients–a simulation study. BMC Medical Research Methodology 10: pp. 24 CrossRef
- Booth, CM, Eisenhauer, EA (2012) Progression-free survival: Meaningful or simply measurable?. Journal of Clinical Oncology 30: pp. 1030-1033 CrossRef
- Bonnetain, F, Bosset, JF, Gerard, JP, Calais, G, Conroy, T, Mineur, L, Bouche, O, Maingon, P, Chapet, O, Radosevic-Jelic, L, Methy, N, Collette, L (2012) What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?. European Journal of Cancer 48: pp. 1781-1790 CrossRef
- Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Quality of Life Research
Volume 24, Issue 1 , pp 5-18
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Health-related quality of life
- Clinical trials
- Longitudinal analysis
- Time to deterioration
- Industry Sectors
- Author Affiliations
- 1. Quality of Life in Oncology Clinical Research Platform, Besançon, France
- 2. Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besançon, 2 Place Saint-Jacques, 25030, Besançon Cedex, France
- 3. Public Health Laboratory, EA 3279, Aix-Marseille University, Marseille, France
- 4. Medical Oncology Department, University Hospital Saint-Antoine, Paris, France
- 5. Gercor, Clinical Research Group in Oncology, Paris, France
- 6. Department of Biostatistics, Regional Cancer Institute, Montpellier, France
- 7. Pneumology Department, University Hospital of Besançon, Besançon, France
- 8. Medical Oncology Department, University Hospital of Besançon, Besançon, France